We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Pasteur Licenses Deafness Diagnostic to Nanogen

By HospiMedica staff writers
Posted on 06 Nov 2003
Exclusive rights in Europe to certain patents and patent applications relating to detection of mutations in the GJB2 gene for the diagnosis of hereditary deafness have been licensed by Institut Pasteur (Paris, France) to Nanogen, Inc. More...
(San Diego, CA, USA). Financial terms were not disclosed.

Nanogen plans to develop a molecular diagnostic product that can be customized by European testing laboratories to screen newborns for hereditary deafness. The GJB2 gene, which encodes a protein called connexin 26, was demonstrated to be associated with 25-50% of cases of hereditary deafness in Western countries and those around the Mediterranean Sea. About one to three in every 1,000 infants born have profound hearing loss, making it one of the most common disabilities in newborns.
.
Universal newborn screening for hearing loss using auditory or behavioral tests has been widely adopted. However, genetic testing can not only help predict hearing loss but identify the cause of loss and predict whether it will deteriorate. Nanogen develops and commercializes molecular diagnostic products for the gene-based testing market.

"There is no genetic test available in Europe to identify whether infants have inherited deafness, and we've secured exclusive rights to intellectual property for this important gene from Insitut Pasteur, a major pioneer in research into the genetics of deafness,” said Howard C. Birndorf, chairman and CEO of Nanogen.





Related Links:
Institut Pasteur
Nanogen

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.